Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
Auteurs / Authors: J. Mazières, C. Lafitte, C. Ricordel, L. Greillier, J. Pujol, G. Zalcman, C. Domblides, J. Madelaine, J. Bennouna, C. Mascaux, D. Moro-Sibilot, F. Pinquié, A. Cortot, J. Otto, J. Cadranel, A. Langlais, F. Morin, V. Westeel, B. Besse
Journal / Conference: ASCO
Année / Year: 2021
PMID: Poster discussion
Lien vers la publication: https://meetinglibrary.asco.org/record/197365/abstract
